Cytochrome P450 1B1 (CYP1B1) (CYP1B1)

Cytochrome P450 1B1 (CYP1B1) is a heme-thiolate monooxygenase enzyme primarily localized in the endoplasmic reticulum that catalyzes the oxidative metabolism of estrogens and various xenobiotics (UniProt: Q16678). It is widely recognized as a universal tumor-associated antigen because it is overexpressed in a vast array of human cancers—including breast, prostate, and lung—while showing minimal expression in normal tissues (PMID: 11133371). This unique expression profile allows CYP1B1 to serve as a target for immunotherapy, such as the ZVEX-CYP1B1 vaccine, and for prodrugs like Phortibi that are selectively activated into cytotoxic agents within tumor cells (PMID: 21143455). Additionally, CYP1B1 is critical for ocular development, and loss-of-function mutations are the leading cause of primary congenital glaucoma (PMID: 9042921). Therapeutic interventions targeting CYP1B1 focus on inhibiting its role in metabolic activation of carcinogens or exploiting its presence to direct immune-mediated destruction of malignant cells. The enzyme's ability to hydroxylate 17beta-estradiol specifically at the C-4 position is also linked to the formation of catechol estrogens, which are implicated in hormonal carcinogenesis. Consequently, CYP1B1 represents a multi-faceted target in oncology, serving as both a biomarker for malignancy and a functional site for therapeutic intervention.

Other names

CYPIB1CP1BGLC3AP4501B1Cytochrome P450 family 1 subfamily B member 1Tumor-associated antigen CYP1B1

Inhibition of enzymatic activity to prevent pro-carcinogen activation, metabolic activation of prodrugs into cytotoxic agents, or induction of T-cell mediated immune responses against cells expressing the antigen.